论文部分内容阅读
超广谱头孢菌素——头孢哌酮粉针剂(Cefoperazone)是日本富山(Toyama)化学公司1979年试制成功的一个第三代头孢菌素,同年向美国辉瑞公司(Pfizer)转让技术与销售权,1980年辉瑞公司以商品名——Cefobid投入市场,1986年世界销售额预计为2.5亿美元。 上海第三制药厂与太原制药厂于1983年研制成功国产的头孢哌酮,并于1984年11月至1985年5月在上海华山医院、儿科医院、中山医院、青浦朱家角人民医院与第八人民医院等13所医院进行临床考核。1985年9月,由国家医药管理局在上海召开了国产头孢哌酮的技术鉴定会。
Cefoperazone is a third generation cephalosporin successfully manufactured by Toyama Chemical Company in 1979. In the same year, Cefoperazone transferred its technology and marketing rights to Pfizer In 1980, Pfizer was introduced into the market under the trade name Ceefobid. In 1986, world sales were estimated to be 250 million U.S. dollars. Shanghai Third Pharmaceutical Factory and Taiyuan Pharmaceutical Factory in 1983 successfully developed domestic cefoperazone, and in November 1984 to May 1985 in Shanghai Huashan Hospital, Pediatric Hospital, Zhongshan Hospital, Qingpu Zhujiajiao People’s Hospital and the Eighth People Hospitals and other 13 hospitals for clinical assessment. September 1985, by the State Pharmaceutical Administration in Shanghai held a domestic appraisal of cefoperazone.